Publications
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 and before
2023
Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations.
Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, Bruno B, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jaeger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sanchez-Guijo FM, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden J, Thieblemont C, Topp MS, Zinzani PL, Gribben JG, Bonini C, Sureda Balari A, Yakoub-Agha I.
Blood. 2023 Jun 10:blood.2023020578. doi: 10.1182/blood.2023020578. PubMed
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteria.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG.
Cancer Imaging. 2023 May 15;23(1):44. doi: 10.1186/s40644-023-00566-7. PubMed
An International Survey on Grading, Diagnosis, and Management of Immune Effector Cell-Associated Hematotoxicity (ICAHT) Following CAR T-cell Therapy on Behalf of the EBMT and EHA.
Rejeski K, Greco R, Onida F, Sánchez-Ortega I, Bonini C, Sureda A, Gribben JG, Yakoub-Agha I, Subklewe M.
Hemasphere. 2023 Apr 27;7(5):e889. doi: 10.1097/HS9.0000000000000889. eCollection 2023 May. PubMed
Prognostic value of pre-infusion tumor growth rate for patients with lymphoma receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG.
Cytotherapy. 2023 Apr 11:S1465-3249(23)00069-5. doi: 10.1016/j.jcyt.2023.03.007. PubMed
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M.
Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. doi: 10.1007/s00262-023-03439-x. Epub 2023 Apr 11. PubMed
Influence of Adipose Tissue Distribution, Sarcopenia, and Nutritional Status on Clinical Outcomes After CD19 CAR T-cell Therapy.
Rejeski K, Cordas Dos Santos DM, Parker NH, Bücklein VL, Winkelmann M, Jhaveri KS, Liu L, Trinkner P, Günther S, Karschnia P, Blumenberg V, Schmidt C, Kunz WG, von Bergwelt-Baildon M, Jain MD, Theurich S, Subklewe M.
Cancer Immunol Res. 2023 Jun 2;11(6):707-719. doi: 10.1158/2326-6066.CIR-22-0487. PubMed
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, Petrera A, Müller N, Hildebrand F, Frölich L, Karschnia P, Schmidt C, Cordas Dos Santos DM, Piñana JL, Müller F, Martin AA, Dreyling M, von Bergwelt-Baildon M, Barba P, Subklewe M, Bücklein VL.
Hemasphere. 2023 Apr 5;7(4):e858. doi: 10.1097/HS9.0000000000000858. eCollection 2023 Apr. PubMed
The race is on: bispecifics vs CAR T-cells in B-cell lymphoma.
Gurumurthi A, Westin JR, Subklewe M.
Blood Adv. 2023 Apr 10:bloodadvances.2022009066. doi: 10.1182/bloodadvances.2022009066. PubMed
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy.
Stein-Thoeringer CK, Saini NY, Zamir E, Blumenberg V, Schubert ML, Mor U, Fante MA, Schmidt S, Hayase E, Hayase T, Rohrbach R, Chang CC, McDaniel L, Flores I, Gaiser R, Edinger M, Wolff D, Heidenreich M, Strati P, Nair R, Chihara D, Fayad LE, Ahmed S, Iyer SP, Steiner RE, Jain P, Nastoupil LJ, Westin J, Arora R, Wang ML, Turner J, Menges M, Hidalgo-Vargas M, Reid K, Dreger P, Schmitt A, Müller-Tidow C, Locke FL, Davila ML, Champlin RE, Flowers CR, Shpall EJ, Poeck H, Neelapu SS, Schmitt M, Subklewe M, Jain MD, Jenq RR, Elinav E.
Nat Med. 2023 Mar 13. doi: 10.1038/s41591-023-02234-6. PubMed
Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia.
Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti CA, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller PJ, Dörr J, Seifert M, Cadilha BL, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner C, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S.
Nat Biotechnol. 2023 Mar 13. doi: 10.1038/s41587-023-01684-0. PubMed
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Fan J, Adams A, Sieg N, Heger JM, Gödel P, Kutsch N, Kaul D, Teichert M, von Tresckow B, Bücklein V, Goesmann G, Li M, Struve N, Trommer M, Linde P, Rosenbrock J, Celik E, Penack O, Stuschke M, Subklewe M, Belka C, von Bergwelt-Baildon M, Borchmann P, Marnitz S, Baues C.
Radiother Oncol. 2023 Feb 25;183:109580. doi: 10.1016/j.radonc.2023.109580. PubMed
STING agonism turns human T cells into interferon-producing cells but impedes their functionality.
Kuhl N, Linder A, Philipp N, Nixdorf D, Fischer H, Veth S, Kuut G, Xu TT, Theurich S, Carell T, Subklewe M, Hornung V.
EMBO Rep. 2023 Mar 6;24(3):e55536. doi: 10.15252/embr.202255536. Epub 2023 Jan 27. PubMed
Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
Dreger P, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp M, Schroers R, Wolff D, Thomas S, Kröger N, Bethge WA; German Lymphoma Alliance (GLA); German Stem Cell Transplantation Registry (DRST).
Bone Marrow Transplant. 2023 Feb;58(2):229-232. doi: 10.1038/s41409-022-01867-4. Epub 2022 Nov 22. PubMed
Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia.
Ruzicka M, Wurm S, Lindner L, Dreyling M, von Bergwelt-Baildon M, Boeck S, Giessen-Jung C, Milani V, Stemmler JH, Subklewe M, Weigert O, Spiekermann K.
Infection. 2023 Feb;51(1):231-238. doi: 10.1007/s15010-022-01909-5. Epub 2022 Oct 4. PubMed
Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig A, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K.
Blood. 2023 Mar 2;141(9):1023-1035. doi: 10.1182/blood.2021015246. PubMed
WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in mice.
Ghalandary M, Gao Y, Amend D, Kutkaite G, Vick B, Spiekermann K, Rothenberg-Thurley M, Metzeler KH, Marcinek A, Subklewe M, Menden MP, Jurinovic V, Bahrami E, Jeremias I.
Blood. 2023 Feb 23;141(8):955-960. doi: 10.1182/blood.2022016411. PubMed
In vivo dynamics and anti-tumor effects of EpCAM-directed CAR T-cells against brain metastases from lung cancer.
Xu T, Karschnia P, Cadilha BL, Dede S, Lorenz M, Seewaldt N, Nikolaishvili E, Müller K, Blobner J, Teske N, Herold JJ, Rejeski K, Langer S, Obeck H, Lorenzini T, Mulazzani M, Zhang W, Ishikawa-Ankerhold H, Buchholz VR, Subklewe M, Thon N, Straube A, Tonn JC, Kobold S, von Baumgarten L.
Oncoimmunology. 2023 Jan 13;12(1):2163781. doi: 10.1080/2162402X.2022.2163781. eCollection 2023. PubMed
2022
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG.
Eur J Nucl Med Mol Imaging. 2022 Dec 14. doi: 10.1007/s00259-022-06075-2. PubMed
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Dong J, Adhikary S, Zhou L, Schuberth PC, Faghmous I, Masouleh BK, Houot R.
J Hematol Oncol. 2022 Dec 10;15(1):170. doi: 10.1186/s13045-022-01379-0. PubMed
A polyamine-centric, blood-based metabolite panel predictive of poor response to CAR-T cell therapy in large B cell lymphoma.
Fahrmann JF, Saini NY, Chia-Chi C, Irajizad E, Strati P, Nair R, Fayad LE, Ahmed S, Lee HJ, Iyer S, Steiner R, Vykoukal J, Wu R, Dennison JB, Nastoupil L, Jain P, Wang M, Green M, Westin J, Blumenberg V, Davila M, Champlin R, Shpall EJ, Kebriaei P, Flowers CR, Jain M, Jenq R, Stein-Thoeringer CK, Subklewe M, Neelapu SS, Hanash S.
Cell Rep Med. 2022 Nov 15;3(11):100720. doi: 10.1016/j.xcrm.2022.100720. PubMed
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR-T cell therapy.
Reimann H, Kremer AN, Blumenberg V, Schmidt KG, Aigner M, Jacobs B, Eisenhauer N, Kämpf A, Roesler W, Kharboutli S, Mougiakakos D, Lang V, Lischer C, Irrgang P, Leppkes M, Gonzalez JV, Krönke G, Kremer AE, Tenbusch M, Bruns H, Harrer T, Müller F, Schett G, Mackensen A, Subklewe M, Völkl S.
Blood Adv. 2022 Oct 7:bloodadvances.2022007806. doi: 10.1182/bloodadvances.2022007806. PubMed
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall Survival.
Winkelmann M, Rejeski K, Blumenberg V, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG.
Hemasphere. 2022 Sep 27;6(10):e781. doi: 10.1097/HS9.0000000000000781. eCollection 2022 Oct. PubMed
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessment.
Winkelmann M, Bücklein VL, Blumenberg V, Rejeski K, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG.
Front Oncol. 2022 Sep 8;12:974029. doi: 10.3389/fonc.2022.974029. eCollection 2022. PubMed
Accumulation of mutations in antibody and CD8 T cell epitopes in a B cell depleted lymphoma patient with chronic SARS-CoV-2 infection.
Khatamzas E, Antwerpen MH, Rehn A, Graf A, Hellmuth JC, Hollaus A, Mohr AW, Gaitzsch E, Weiglein T, Georgi E, Scherer C, Stecher SS, Gruetzner S, Blum H, Krebs S, Reischer A, Leutbecher A, Subklewe M, Dick A, Zange S, Girl P, Müller K, Weigert O, Hopfner KP, Stemmler HJ, von Bergwelt-Baildon M, Keppler OT, Wölfel R, Muenchhoff M, Moosmann A.
Nat Commun. 2022 Sep 23;13(1):5586. doi: 10.1038/s41467-022-32772-5. PubMed
Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors.
Stock S, Benmebarek MR, Kluever AK, Darowski D, Jost C, Stubenrauch KG, Benz J, Freimoser-Grundschober A, Moessner E, Umana P, Subklewe M, Endres S, Klein C, Kobold S.
J Immunother Cancer. 2022 Jul;10(7):e005054. doi: 10.1136/jitc-2022-005054. PubMed
T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals.
Zieger N, Kazerani M, Nicholls A, Vick B, Wulf J, Straub T, Scheurer M, Muth A, Hänel G, Nixdorf D, Sponheimer M, Ohlmeyer M, Lacher SM, Brauchle B, Marcinek A, Rohrbacher L, Leutbecher A, Rejeski K, Weigert O, von Bergwelt-Baildon M, Theurich S, Kischel R, Jeremias I, Bücklein VL, Subklewe M.
Blood. 2022 Jul 25:blood.2022015956. doi: 10.1182/blood.2022015956. PubMed
Clinical Significance of Transient Asymptomatic Elevations in Aminotransferase (TAEAT) in Oncology.
Lewis JH, Khaldoyanidi SK, Britten CD, Wei AH, Subklewe M.
Am J Clin Oncol. 2022 Aug 1;45(8):352-365. doi: 10.1097/COC.0000000000000932. Epub 2022 Jul 18. PubMed
Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy.
Rejeski K, Burchert A, Iacoboni G, Sesques P, Fransecky L, Buecklein V, Trenker C, Hernani R, Naumann R, Schäfer JA, Blumenberg V, Schmidt C, Sohlbach K, von Bergwelt-Baildon M, Bachy E, Barba P, Subklewe M.
Blood Adv. 2022 Jun 24:bloodadvances.2022007776. doi: 10.1182/bloodadvances.2022007776. PubMed
Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T for Richter transformed DLBCL.
Rejeski K, Wu Z, Blumenberg V, Kunz WG, Mueller S, Kajigaya S, Gao S, Buecklein V, Frölich L, Schmidt C, von Bergwelt-Baildon M, Feng X, Young NS, Subklewe M.
Blood. 2022 Jul 1:blood.2022017015. doi: 10.1182/blood.2022017015. PubMed
Integrated multiomic approach for identification of novel immunotherapeutic targets in AML.
Köhnke T, Liu X, Haubner S, Bücklein V, Hänel G, Krupka C, Solis-Mezarino V, Herzog F, Subklewe M.
Biomark Res. 2022 Jun 10;10(1):43. doi: 10.1186/s40364-022-00390-4. PubMed
Leukemic stem cells as a target for eliminating acute myeloid leukemia: Gaps in translational research.
Khaldoyanidi SK, Hindoyan A, Stein A, Subklewe M.
Crit Rev Oncol Hematol. 2022 Jul;175:103710. doi: 10.1016/j.critrevonc.2022.103710. Epub 2022 May 16. Review. PubMed
The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL.
Rejeski K, Perez A, Iacoboni G, Penack O, Bücklein V, Jentzsch L, Mougiakakos D, Johnson G, Arciola B, Carpio C, Blumenberg V, Hoster E, Bullinger L, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge W, Barba P, Jain MD, Subklewe M.
J Immunother Cancer. 2022 May;10(5):e004475. doi: 10.1136/jitc-2021-004475. PubMed
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P, Rejeski K, Winkelmann M, Schöberl F, Bücklein VL, Blumenberg V, Schmidt C, Blobner J, von Bergwelt-Baildon M, Tonn JC, Kunz WG, Subklewe M, von Baumgarten L.
Neurology. 2022 May 24;98(21):884-889. doi: 10.1212/WNL.0000000000200608. Epub 2022 Mar 29. PubMed
GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany.
Bethge WA, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet EM, Wulf GG, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus CD, Vucinic V, Mougiakakos D, Topp MS, Fante MA, Schroers R, Bayir LM, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen DW, Lengerke C, Kroeger N, Dreger P.
Blood. 2022 Mar 22:blood.2021015209. doi: 10.1182/blood.2021015209. PubMed
Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.
Iacoboni G, Rejeski K, Villacampa G, van Doesum JA, Chiappella A, Bonifazi F, Lopez-Corral L, van Aalderen M, Kwon M, Martínez-Cibrian N, Bramanti S, Reguera-Ortega JL, Camacho-Arteaga L, Schmidt C, Marín-Niebla A, Kersten MJ, Martin Garcia-Sancho A, Zinzani PL, Corradini P, van Meerten T, Subklewe M, Barba P.
Blood Adv. 2022 Jun 28;6(12):3606-3610. doi: 10.1182/bloodadvances.2021006922. PubMed
Increased visceral fat distribution and body composition impact cytokine release syndrome onset and severity after CD19 CAR-T in advanced B-cell malignancies.
Dos Santos DMC, Rejeski K, Winkelmann M, Liu L, Trinkner P, Günther S, Bücklein VL, Blumenberg V, Schmidt C, Kunz WG, Von Bergwelt-Baildon M, Theurich S, Subklewe M.
Haematologica. 2022 Feb 17. doi: 10.3324/haematol.2021.280189. PubMed
Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T cell treatment.
Schoeberl F, Tiedt S, Schmitt A, Blumenberg V, Karschnia P, Granja Burbano V, Buecklein V, Rejeski K, Schmidt C, Busch G, von Bergwelt-Baildon M, Tonn JC, Schmitt M, Subklewe M, von Baumgarten L.
Blood Adv. 2022 Jan 18:bloodadvances.2021006144. doi: 10.1182/bloodadvances.2021006144. PubMed
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party.
Tettero JM, Freeman S, Buecklein V, Venditti A, Maurillo L, Kern W, Walter RB, Wood BL, Roumier C, Philippé J, Denys B, Jorgensen JL, Bene MC, Lacombe F, Plesa A, Guzman ML, Wierzbowska A, Czyz A, Ngai LL, Schwarzer A, Bachas C, Cloos J, Subklewe M, Fuering-Buske M, Buccisano F.
Hemasphere. 2021 Dec 22;6(1):e676. doi: 10.1097/HS9.0000000000000676. eCollection 2022 Jan. PubMed
2021
Blood DCs activated with R848 and poly(I:C) induce antigen-specific immune responses against viral and tumor-associated antigens.
Hänel G, Angerer C, Petry K, Lichtenegger FS, Subklewe M.
Cancer Immunol Immunother. 2022 Jul;71(7):1705-1718. doi: 10.1007/s00262-021-03109-w. Epub 2021 Nov 25. PubMed
SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells.
Tahk S, Vick B, Hiller B, Schmitt S, Marcinek A, Perini ED, Leutbecher A, Augsberger C, Reischer A, Tast B, Humpe A, Jeremias I, Subklewe M, Fenn NC, Hopfner KP.
J Hematol Oncol. 2021 Sep 27;14(1):155. doi: 10.1186/s13045-021-01163-6. PubMed
[Practical aspects of the application of CAR T cells and management of their toxicities.]
Bücklein V, Blumenberg V, Subklewe M.
Dtsch Med Wochenschr. 2021 Sep;146(17):1129-1137. doi: 10.1055/a-1303-8708. PubMed
Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC specific T-cell bispecific antibody.
Augsberger C, Hänel G, Xu W, Pulko V, Hanisch L, Augustin A, Challier J, Hunt K, Vick B, Rovatti P, Krupka C, Rothe M, Schönle A, Sam J, Lezan E, Ducret A, Ortiz-Franyuti D, Walz A, Benz J, Bujotzek A, Lichtenegger FS, Gassner C, Carpy A, Lyamichev V, Patel J, Konstandin N, Tunger A, Schmitz M, von Bergwelt-Baildon M, Spiekermann K, Vago L, Jeremias I, Marrer-Berger E, Umaña P, Klein C, Subklewe M.
Blood. 2021 Dec 23;138(25):2655-2669. doi: 10.1182/blood.2020010477. PubMed
[Update 2021: COVID-19 from the Perspective of Haematology and Haemostaseology.]
Spiekermann K, Subklewe M, Hildebrandt M, Humpe A, von Bergwelt-Baildon M.
Dtsch Med Wochenschr. 2021 Jul;146(13-14):899-903. doi: 10.1055/a-1449-4934. PubMed
COVID-19 in Patients Receiving CD20-Depleting Immunochemotherapy for B-Cell Lymphoma.
Gaitzsch E, Passerini V, Khatamzas E, Strobl C, Muenchhoff M, Scherer C, Osterman A, Heide M, Reischer A, Subklewe M, Leutbecher A, Tast B, Ruhle A, Weiglein T, Stecher S-S, Stemmler HJ, Dreyling M, Girl P, Georgi E, Wölfel R, Mateyka L, D’Ippolito E, Schober K, Busch D, Kager J, Spinner CD, Treiber M, Rasch S, Lahmer T, Iakoubov R, Schneider J, Protzer U, Winter C, Ruland J, Quante M, Keppler OT, von Bergwelt-Baildon M, Hellmuth J, Weigert O.
HemaSphere. 2021 Jun 28;5(7):e603. doi: 10.1097/HS9.0000000000000603. eCollection 2021 Jul., PubMed
CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma.
Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M.
Blood. 2021 Jun 24;blood.2020010543. doi: 10.1182/blood.2020010543. PubMed
Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.
Cadilha BL, Benmebarek M-R, Dorman K, Oner A, Lorenzini T, Obeck H, Vänttinen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Märkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S.
Sci Adv. 2021 Jun 9;7(24):eabi5781. doi: 10.1126/sciadv.abi5781. Print 2021 Jun. PubMed
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, Bishop MR, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R.
Lancet. 2021 Jun 3;S0140-6736(21)01222-8. doi: 10.1016/S0140-6736(21)01222-8. PubMed
T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours.
Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S.
Nat Biomed Eng. 2021 Jun 3. doi: 10.1038/s41551-021-00737-6. PubMed
Sarcoid-Like Reaction in Non-Hodgkin's Lymphoma-A Diagnostic Challenge for Deauville Scoring on 18 F-FDG PET/CT Imaging.
Winkelmann M, Rejeski K, Subklewe M, Ricke J, Unterrainer M, Rudelius M, Kunz WG.
Diagnostics (Basel). 2021 May 31;11(6):1009. doi: 10.3390/diagnostics11061009. PubMed
CAR T-Cells for CNS Lymphoma: Driving into New Terrain?
Karschnia P, Blobner J, Teske N, Schöberl F, Fitzinger E, Dreyling M, Tonn JC, Thon N, Subklewe M, von Baumgarten L.
Cancers (Basel). 2021 May 20;13(10):2503. doi: 10.3390/cancers13102503. Review. PubMed
CAR T-Cells for Glioblastoma: Current Concepts, Challenges and Future Perspectives.
Karschnia P, Teske N, Thon N, Subklewe M, Tonn JC, Dietrich J, von Baumgarten L.
Neurology. 2021 May 13;10.1212/WNL.0000000000012193. doi: 10.1212/WNL.0000000000012193. PubMed
T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments.
Daver N, Alotaibi AS, Bücklein V, Subklewe M.
Leukemia. 2021 May 5. doi: 10.1038/s41375-021-01253-x. PubMed
Chimeric Antigen Receptor-Modified T Cells and T Cell-Engaging Bispecific Antibodies: Different Tools for the Same Job.
Schwerdtfeger M, Benmebarek MR, Endres S, Subklewe M, Desiderio V, Kobold S.
Curr Hematol Malig Rep. 2021 Apr 30. doi: 10.1007/s11899-021-00628-2. PubMed
The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
Rohrbacher L, Brauchle B, Ogrinc Wagner A, von Bergwelt-Baildon M, Bücklein VL, Subklewe M.
Front Immunol. 2021 Mar 15;12:608625. doi: 10.3389/fimmu.2021.608625. eCollection 2021. PubMed
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy.
Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T.
Blood 2021 Feb 25;137(8):1037-1049. doi: 10.1182/blood.2020006921. PubMed
Clinicopathologic Findings in Fatal Neurotoxicity After Adoptive Immunotherapy With CD19-Directed CAR T-Cells.
Karschnia P, Strübing F, Teske N, Blumenberg V, Bücklein VL, Schmidt C, Schöberl F, Dimitriadis K, Forbrig R, Stemmler H-J, Tonn J-C, von Bergwelt-Baildon M, Subklewe M, von Baumgarten L.
Hemasphere. 2021 Feb 10;5(3):e533. doi: 10.1097/HS9.0000000000000533. PubMed
Immune Checkpoint Blockade for Aspergillosis and Mucormycosis Coinfection.
Banck JC, Mueller N, Mellinghoff SC, Thelen M, Fraccaroli A, Blumenberg V, Koehler P, Kunz WG, Rudelius M, Schrötzlmair F, Subklewe M, Schlößer HA, Tischer J, Cornely OA, Lindner LH, von Bergwelt-Baildon M.
Hemasphere. 2021 Feb 10;5(3):e530. doi: 10.1097/HS9.0000000000000530. PubMed
Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report.
Rejeski K, Kunz WG, Rudelius M, Bücklein V, Blumenberg V, Schmidt C, Karschnia P, Schöberl F, Dimitriadis K, von Baumgarten L, Stemmler J, Weigert O, Dreyling M, von Bergwelt-Baildon M, Subklewe M.
BMC Infect Dis. 2021 Jan 28;21(1):121. doi: 10.1186/s12879-020-05755-4. PubMed
BiTEs better than CAR T cells
Subklewe M.
Blood Adv. 2021 Jan 26;5(2):607-612. doi: 10.1182/bloodadvances.2020001792. PubMed
Immune Biology of Acute Myeloid Leukemia: Implications for Immunotherapy.
Khaldoyanidi S, Nagorsen D, Stein A, Ossenkoppele G, Subklewe M.
J Clin Oncol. 2021 Jan 12:JCO2000475. doi: 10.1200/JCO.20.00475. Review PubMed
A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR, Cadilha BL, Herrmann M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger C, Brauchle B, Rohrbacher L, Oner A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein C, Subklewe M, Endres S, Hopfner KP, Kobold S.
Leukemia 2021 Jan 7:1-15. doi: 10.1038/s41375-020-01109-w. PubMed
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P., Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh S-P, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH
Leukemia 2021 Jan;35(1):62-74. doi: 10.1038/s41375-020-0773-5 PubMed
2020
Fusion of Bacterial Flagellin to a Dendritic Cell-Targeting αCD40 Antibody Construct Coupled With Viral or Leukemia-Specific Antigens Enhances Dendritic Cell Maturation and Activates Peptide-Responsive T Cells.
Schmitt S, Tahk S, Lohner A, Hänel G, Maiser A, Hauke M, Patel L, Rothe M, Josenhans C, Leonhardt H, Griffioen M, Deiser K, Fenn NC, Hopfner KP, Subklewe M.
Front Immunol. 2020 Nov 12;11:602802. doi: 10.3389/fimmu.2020.602802. PubMed
CLEC12A and CD33 co-expression as preferential target on pediatric AML for combinatorial immunotherapy.
Willier S, Rothämel P, Hastreiter M, Wilhelm J, Stenger D, Blaeschke F, Rohlfs M, Kaeuferle T, Schmid I, Albert MH, Binder V, Subklewe M, Klein C, Feuchtinger T.
Blood 2020 Oct 22;blood.2020006921. doi: 10.1182/blood.2020006921. PubMed
Transformation of diffuse large B cell lymphoma into dendritic sarcoma under CAR T cell therapy detected on 18F-FDG PET/CT.
Winkelmann M, Rejeski K, Unterrainer M, Schmidt C, Ruzicka M, Ricke J, Rudelius M, Subklewe M, Kunz WG.
Eur J Nucl Med Mol Imaging 2020 Aug 19. doi: 10.1007/s00259-020-05000-9. PubMed
[COVID-19 from the Perspective of Haematology and Haemostaseology].
Spiekermann K, Subklewe M, Hildebrandt M, Humpe A, von Bergwelt-Baildon M.
Dtsch Med Wochenschr. 2020 Jul;145(15):1044-1050. doi: 10.1055/a-1164-4191. PubMed
Characterization of a Novel FLT3 BiTE® Antibody Construct for the Treatment of Acute Myeloid Leukemia.
Brauchle B, Goldstein RL, Karbowski CM, Henn A, Li C-M, Bücklein VL, Krupka C, Boyle MC, Koppikar P, Haubner S, Wahl J, Dahlhoff C, Raum T, Rardin MJ, Sastri C, Rock DA, von Bergwelt-Baildon M, Frank B, Metzeler KH, Case R, Friedrich M, Balazs M, Spiekermann K, Coxon A, Subklewe M, Arvedson T.
Mol. Cancer Ther. 2020 Jun 9; doi: 10.1158/1535-7163.MCT-19-1093. PubMed
The BiTE (bispecific T-cell engager) platform: Development and future potential of a targeted immuno-oncology therapy across tumor types.
Einsele H, Borghaei H, Orlowski RZ, Subklewe M, Roboz GJ, Zugmaier G, Kufer P, Iskander K, Kantarjian HM.
Cancer 2020 Jul 15;126(14):3192-3201. doi: 10.1002/cncr.32909. Review PubMed
A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas.
Orth MF, Buecklein VL, Kampmann E, Subklewe M, Noessner E, Cidre-Aranaz F, Romero-Pérez L, Wehweck FS, Lindner L, Issels R, Kirchner T, Altendorf-Hofmann A, Grünewald TGP, Knösel T.
Cancer Immunol Immunother. 2020 Jul;69(7):1353-1362. doi: 10.1007/s00262-020-02552-5. PubMed
Ten things the hematologist wants you to know about CAR-T cells.
Böll B, Subklewe M, von Bergwelt-Baildon M.
Intensive Care Med. 2020 Jun;46(6):1243-1245. doi: 10.1007/s00134-020-06002-9. doi: 10.1007/s00134-020-06002-9. PubMed
Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia.
Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, Konstandin NP, Dufour A, Schneider S, Neusser M, Ksienzyk B, Greif PA, Subklewe M, Faldum A, Bohlander SK, Braess J, Wörmann B, Krug U, Berdel WE, Hiddemann W, Spiekermann K, Metzeler KH.
Leukemia 2020 Mar 30; doi: 10.1038/s41375-020-0806-0. PubMed
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study.
Montesinos P, Roboz GJ, Bulabois CE, Subklewe M, Platzbecker U, Ofran Y, Papayannidis C, Wierzbowska A, Shin HJ, Doronin V, Deneberg S, Yeh SP, Ozcan MA, Knapper S, Cortes J, Pollyea DA, Ossenkoppele G, Giralt S, Döhner H, Heuser M, Xiu L, Singh I, Huang F, Larsen JS, Wei AH.
Leukemia 2020 Mar 16; doi:10.1038/s41375-020-0773-5. PubMed
Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial.
Lichtenegger FS, Schnorfeil FM, Rothe M, Deiser K, Altmann T, Bücklein VL, Köhnke T, Augsberger C, Konstandin NP, Spiekermann K, Moosmann A, Boehm S, Boxberg M, Heemskerk MH, Goerlich D, Wittmann G, Wagner B, Hiddemann W, Schendel DJ, Kvalheim G, Bigalke I, Subklewe M.
Clin Transl Immunology. 2020 Mar 3;9(3):e1117. doi: 10.1002/cti2.1117. PubMed
2019
RIG-I-based immunotherapy enhances survival in preclinical AML models and sensitizes AML cells to checkpoint blockade.
Ruzicka M, Koenig LM, Formisano S, Boehmer DFR, Vick B, Heuer EM, Meinl H, Kocheise L, Zeitlhöfler M, Ahlfeld J, Kobold S, Endres S, Subklewe M, Duewell P, Schnurr M, Jeremias I, Lichtenegger FS, Rothenfusser S.
Leukemia 2019 Nov 18;8(5). doi: 10.1038/s41375-019-0639-x. PubMed
Determinants of response and resistance to CAR T cell therapy.
Lesch S, Benmebarek MR, Cadilha BL, Stoiber S, Subklewe M, Endres S, Kobold S.
Semin Cancer Biol. 2019 Nov 6; pii: S1044-579X(19)30219-6. doi: 10.1016/j.semcancer.2019.11.004. Review PubMed
Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis.
Grunwald VV, Hentrich M, Schiel X, Dufour A, Schneider S, Neusser M, Subklewe M, Fiegl M, Hiddemann W, Spiekermann K, Rothenberg-Thurley M, Metzeler KH.
Blood Adv. 2019 Sep 24;3(18):2696-2699. doi: 10.1182/bloodadvances.2019000265. PubMed
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
Subklewe M, von Bergwelt-Baildon M, Humpe A.
Transfus Med Hemother. 2019 Feb;46(1):15-24. doi: 10.1159/000496870. Review PubMed
Advances in cancer immunotherapy 2019 - latest trends.
Kruger S, Ilmer M, Kobold S, Cadilha BL, Endres S, Ormanns S, Schuebbe G, Renz BW, D'Haese JG, Schloesser H, Heinemann V, Subklewe M, Boeck S, Werner J, von Bergwelt-Baildon M.
J Exp Clin Cancer Res. 2019 Jun 19;38(1):268. doi: 10.1186/s13046-019-1266-0. Review PubMed
Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia.
Van Acker HH, Versteven M, Lichtenegger FS, Roex G, Campillo-Davo D, Lion E, Subklewe M, Van Tendeloo VF, Berneman ZN, Anguille S.
J Clin Med. 2019 Apr 27;8(5). pii: E579. doi: 10.3390/jcm8050579. Review. PubMed
Response assessment in acute myeloid leukemia by flow cytometry supersedes cytomorphology at time of aplasia, amends cases without molecular residual disease marker and serves as an independent prognostic marker at time of aplasia and post-induction.
Köhnke T, Bücklein V, Rechkemmer S, Schneider S, Rothenberg-Thurley M, Metzeler KH, Sauerland MC, Hiddemann W, Spiekermann K, Subklewe M.
Haematologica. 2019 Apr 4. pii: haematol.2018.215236. doi: 10.3324/haematol.2018.215236. PubMed
Abundant GAD-reactive B cells in GAD-antibody-associated neurological disorders.
Thaler FS, Thaller AL, Biljecki M, Schuh E, Winklmeier S, Mahler CF, Gerhards R, Völk S, Schnorfeil F, Subklewe M, Hohlfeld R, Kümpfel T, Meinl E.
Ann Neurol. 2019 Jan 11. doi: 10.1002/ana.25414. PubMed
2018
Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study.
Braess J, Amler S, Kreuzer KA, Spiekermann K, Lindemann HW, Lengfelder E, Graeven U, Staib P, Ludwig WD, Biersack H, Ko YD, Uppenkamp MJ, De Wit M, Korsten S, Peceny R, Gaska T, Schiel X, Behringer DM, Kiehl MG, Zinngrebe B, Meckenstock G, Roemer E, Medgenberg D, Spaeth-Schwalbe E, Massenkeil G, Hindahl H, Schwerdtfeger R, Trenn G, Sauerland C, Koch R, Lablans M, Faldum A, Görlich D, Bohlander SK, Schneider S, Dufour A, Buske C, Fiegl M, Subklewe M, Braess B, Unterhalt M, Baumgartner A, Wörmann B, Beelen D, Hiddemann W; AML-CG.
Leukemia. 2018 Oct 1. doi: 10.1038/s41375-018-0268-9. PubMed
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia.
Herrmann M, Krupka C, Deiser K, Brauchle B, Marcinek A, Ogrinc Wagner A, Rataj F, Mocikat R, Metzeler KH, Spiekermann K, Kobold S, Fenn NC, Hopfner KP, Subklewe M.
Blood. 2018 Oct 1. doi: 10.1182/blood-2018-05-849802. PubMed
Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells.
Braciak TA, Roskopf CC, Wildenhain S, Fenn NC, Schiller CB, Schubert IA, Jacob U, Honegger A, Krupka C, Subklewe M, Spiekermann K, Hopfner KP, Fey GH, Aigner M, Krause S, Mackensen A, Oduncu FS.
Oncoimmunology. 2018 Jul 30;7(9):e1472195. doi: 10.1080/2162402X.2018.1472195. PubMed
[Challenges in Immuno-Oncology - Possibilities for Optimization].
Shimabukuro-Vornhagen A, Subklewe M, von Bergwelt-Baildon M.
Dtsch Med Wochenschr. 2018 Jul;143(14):1022-1029. doi: 10.1055/a-0549-6987. German. PubMed
Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML.
Haubner S, Perna F, Köhnke T, Schmidt C, Berman S, Augsberger C, Schnorfeil FM, Krupka C, Lichtenegger FS, Liu X, Kerbs P, Schneider S, Metzeler KH, Spiekermann K, Hiddemann W, Greif PA, Herold T, Sadelain M, Subklewe M.
Leukemia. 2018 Jun 26. doi: 10.1038/s41375-018-0180-3. PubMed
Cytokine release syndrome.
Shimabukuro-Vornhagen A, Gödel P, Subklewe M, Stemmler HJ, Schlößer HA, Schlaak M, Kochanek M, Böll B, von Bergwelt-Baildon MS.
J Immunother Cancer. 2018 Jun 15;6(1):56. doi: 10.1186/s40425-018-0343-9. Review. PubMed
Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged ≥ 75 years.
Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, Konstandin NP, Goerlich D, Krug U, Faldum A, Berdel WE, Wörmann B, Braess J, Schneider S, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Metzeler KH.
Haematologica. 2018 Jun 14. doi: 10.3324/haematol.2018.191536. PubMed
Immunosuppression is associated with clinical features and relapse risk of B cell posttransplant lymphoproliferative disorder: A retrospective analysis based on the prospective, international, multicenter PTLD-1 trials.
Zimmermann H, Babel N, Dierickx D, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Dührsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Bachy E, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, Choquet S, Trappe RU.
Transplantation. 2018 May 11. doi: 10.1097/TP.0000000000002269. PubMed
Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
Lichtenegger FS, Rothe M, Schnorfeil FM, Deiser K, Krupka C, Augsberger C, Schlüter M, Neitz J, Subklewe M.
Front Immunol. 2018 Feb 27;9:385. doi: 10.3389/fimmu.2018.00385. PubMed
2017
Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.
Rothenberg-Thurley M, Amler S, Goerlich D, Köhnke T, Konstandin NP, Schneider S, Sauerland MC, Herold T, Hubmann M, Ksienzyk B, Zellmeier E, Bohlander SK, Subklewe M, Faldum A, Hiddemann W, Braess J, Spiekermann K, Metzeler KH.
Leukemia. 2017 Dec 18. doi: 10.1038/leu.2017.350. PubMed
A 29-gene and cytogenetic score for the prediction of resistance to induction treatment in acute myeloid leukemia.
Herold T, Jurinovic V, Batcha AMN, Bamopoulos SA, Rothenberg-Thurley M, Ksienzyk B, Hartmann L, Greif PA, Phillippou-Massier J, Krebs S, Blum H, Amler S, Schneider S, Konstandin N, Sauerland MC, Görlich D, Berdel WE, Wörmann BJ, Tischer J, Subklewe M, Bohlander SK, Braess J, Hiddemann W, Metzeler KH, Mansmann U, Spiekermann K.
Haematologica. 2017 Dec 14. pii: haematol.2017.178442. doi: 10.3324/haematol.2017.178442. PubMed
End-of-treatment positron emission tomography after uniform first-line therapy of B cell posttransplant lymphoproliferative disorder identifies patients at low risk of relapse in the prospective German PTLD registry.
Zimmermann H, Denecke T, Dreyling MH, Franzius C, Reinke P, Subklewe M, Amthauer H, Kneba M, Riess H, Trappe RU.
Transplantation. 2017 Nov 17. doi: 10.1097/TP.0000000000002006. PubMed
The DNA Inflammasome in Human Myeloid Cells Is Initiated by a STING-Cell Death Program Upstream of NLRP3.
Gaidt MM, Ebert TS, Chauhan D, Ramshorn K, Pinci F, Zuber S, O'Duill F, Schmid-Burgk JL, Hoss F, Buhmann R, Wittmann G, Latz E, Subklewe M, Hornung V.
Cell. 2017 Nov 16;171(5):1110-1124.e18. doi: 10.1016/j.cell.2017.09.039. PubMed
Diagnosis of CLL revisited: increased specificity by a modified five-marker scoring system including CD200.
Köhnke T, Wittmann VK, Bücklein VL, Lichtenegger F, Pasalic Z, Hiddemann W, Spiekermann K, Subklewe M.
Br J Haematol. 2017 Nov;179(3):480-487. doi: 10.1111/bjh.14901. PubMed
Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, Metzeler KH, Dörfel D, Salih HR, Jung G, Nößner E, Jeremias I, Hiddemann W, Leonhardt H, Spiekermann K, Subklewe M, Greif PA.
Leukemia. 2017 Aug 14. doi: 10.1038/leu.2017.257. PubMed
A fluorescence in situ hybridization-based screen allows rapid detection of adverse cytogenetic alterations in patients with acute myeloid leukemia.
Sandhöfer N, Metzeler KH, Kakadia PM, Pasalic Z, Hiddemann W, Neusser M, Steinlein O, Fiegl M, Subklewe M, Spiekermann K, Bohlander SK, Schneider S, Braess J.
Genes Chromosomes Cancer. 2017 Aug;56(8):632-638. doi: 10.1002/gcc.22466. PubMed
Recent developments in immunotherapy of acute myeloid leukemia.
Lichtenegger FS, Krupka C, Haubner S, Köhnke T, Subklewe M.
J Hematol Oncol. 2017 Jul 25;10(1):142. doi: 10.1186/s13045-017-0505-0. Review. PubMed
Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C, Lichtenegger FS, Köhnke T, Bögeholz J, Bücklein V, Roiss M, Altmann T, Do TU, Dusek R, Wilson K, Bisht A, Terrett J, Aud D, Pombo-Villar E, Rohlff C, Hiddemann W, Subklewe M.
Oncotarget. 2017 May 30;8(22):35707-35717. doi: 10.18632/oncotarget.16060. PubMed
SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
Ponce LP, Fenn NC, Moritz N, Krupka C, Kozik JH, Lauber K, Subklewe M, Hopfner KP.
Oncotarget. 2017 Feb 14;8(7):11284-11301. doi: 10.18632/oncotarget.14500. PubMed
Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial.
Trappe RU, Dierickx D, Zimmermann H, Morschhauser F, Mollee P, Zaucha JM, Dreyling MH, Döhrsen U, Reinke P, Verhoef G, Subklewe M, Hüttmann A, Tousseyn T, Salles G, Kliem V, Hauser IA, Tarella C, Van Den Neste E, Gheysens O, Anagnostopoulos I, Leblond V, Riess H, et al.
J Clin Oncol. 2017 Feb 10;35(5):536-543. doi: 10.1200/JCO.2016.69.3564 PubMed
Features of Human CD3+CD20+ T Cells.
Schuh E, Berer K, Mulazzani M, Feil K, Meinl I, Lahm H, Krane M, Lange R, Pfannes K, Subklewe M, Gürkov R, Bradl M, Hohlfeld R, Kümpfel T, Meinl E, Krumbholz M.
J Immunol. 2016 Aug 15;197(4):1111-7. doi: 10.4049/jimmunol.1600089. PubMed
Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia.
Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, Görlich D, Schneider S, Konstandin NP, Dufour A, Bräundl K, Ksienzyk B, Zellmeier E, Hartmann L, Greif PA, Fiegl M, Subklewe M, Bohlander SK, Krug U, Faldum A, Berdel WE, Wörmann B, Büchner T, et al.
Blood. 2016 Aug 4;128(5):686-98. doi: 10.1182/blood-2016-01-693879. PubMed
Targeted positron emission tomography imaging of CXCR4 expression in patients with acute myeloid leukemia.
Herhaus P, Habringer S, Philipp-Abbrederis K, Vag T, Gerngross C, Schottelius M, Slotta-Huspenina J, Steiger K, Altmann T, Weißer T, Steidle S, Schick M, Jacobs L, Slawska J, Müller-Thomas C, Verbeek M, Subklewe M, Peschel C, Wester HJ, Schwaiger M, Götze K, Keller U.
Haematologica. 2016 Aug;101(8):932-40. doi: 10.3324/haematol.2016.142976. PubMed
Progressive natural killer cell dysfunction associated with alterations in subset proportions and receptor expression in soft-tissue sarcoma patients.
Böcklein V, Adunka T, Mendler AN, Issels R, Subklewe M, Schmollinger JC, Noessner E.
Oncoimmunology. 2016 Apr 29;5(7):e1178421. doi: 10.1080/2162402X.2016.1178421. PubMed
Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism. Krupka C, Kufer P, Kischel R, Zugmaier G, Lichtenegger FS, Köhnke T, Vick B, Jeremias I, Metzeler KH, Altmann T, Schneider S, Fiegl M, Spiekermann K, Bauerle PA, Hiddemann W, Riethmüller G, Subklewe M.
Leukemia. 2016 Feb;30(2):484-91. doi: 10.1038/leu.2015.214. PubMed
2015
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AML.
Lichtenegger FS, Kondla I, Krempasky M, Weber AL, Herold T, Krupka C, Spiekermann K, Schneider S, Büchner T, Berdel WE, Wörmann BJ, Hiddemann W, Subklewe M.
Cancer Immunol Immunother. 2015 Dec;64(12):1505-15. doi: 10.1007/s00262-015-1755-8. PubMed
Immunotherapy in Tumors.
Kobold S, Duewell P, Schnurr M, Subklewe M, Rothenfusser S, Endres S.
Dtsch Arztebl Int. 2015 Nov 27;112(48):809-15. doi: 10.3238/arztebl.2015.0809. Review. PubMed
Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab.
Köhnke T, Krupka C, Tischer J, Knösel T, Subklewe M.
J Hematol Oncol. 2015 Oct 8;8:111. doi: 10.1186/s13045-015-0213-6. PubMed
Clinical overview of anti-CD19 BiTE(®) and ex vivo data from anti-CD33 BiTE(®) as examples for retargeting T cells in hematologic malignancies.
Zugmaier G, Klinger M, Schmidt M, Subklewe M.
Mol Immunol. 2015 Oct;67(2 Pt A):58-66. doi: 10.1016/j.molimm.2015.02.033. Review. PubMed
T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.
Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R, Hiddemann W, Subklewe M.
J Hematol Oncol. 2015 Jul 30;8:93. doi: 10.1186/s13045-015-0189-2. PubMed
Immunotherapy for Acute Myeloid Leukemia. Lichtenegger FS, Krupka C, Köhnke T, Subklewe M.
Semin Hematol. 2015 Jul;52(3):207-14. doi: 10.1053/j.seminhematol.2015.03.006. Review. PubMed
Bendamustine and the immune system: a wolf in sheep's clothing?
Dreyling M, Subklewe M.
Leuk Lymphoma. 2015 Apr;56(4):837-8. doi: 10.3109/10428194.2015.1024942. PubMed
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
Sandhöfer N, Metzeler KH, Rothenberg M, Herold T, Tiedt S, Groiß V, Carlet M, Walter G, Hinrichsen T, Wachter O, Grunert M, Schneider S, Subklewe M, Dufour A, Frühling S, Klein HG, Hiddemann W, Jeremias I, Spiekermann K.
Leukemia. 2015 Apr;29(4):828-38. doi: 10.1038/leu.2014.305. PubMed
An advanced preclinical mouse model for acute myeloid leukemia using patients' cells of various genetic subgroups and in vivo bioluminescence imaging.
Vick B, Rothenberg M, Sandhöfer N, Carlet M, Finkenzeller C, Krupka C, Grunert M, Trumpp A, Corbacioglu S, Ebinger M, André MC, Hiddemann W, Schneider S, Subklewe M, Metzeler KH, Spiekermann K, Jeremias I.
PLoS One. 2015 Mar 20;10(3):e0120925. doi: 10.1371/journal.pone.0120925. PubMed
Early assessment of minimal residual disease in AML by flow cytometry during aplasia identifies patients at increased risk of relapse.
Köhnke T, Sauter D, Ringel K, Hoster E, Laubender RP, Hubmann M, Bohlander SK, Kakadia PM, Schneider S, Dufour A, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Hiddemann W, Spiekermann K, Subklewe M.
Leukemia. 2015 Feb;29(2):377-86. doi: 10.1038/leu.2014.186. PubMed
2014
New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.
Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I.
Cancer Immunol Immunother. 2014 Oct;63(10):1093-103. doi: 10.1007/s00262-014-1600-5. Review. PubMed
Impaired NK cells and increased T regulatory cell numbers during cytotoxic maintenance therapy in AML.
Lichtenegger FS, Lorenz R, Gellhaus K, Hiddemann W, Beck B, Subklewe M.
Leuk Res. 2014 Aug;38(8):964-9. doi: 10.1016/j.leukres.2014.05.014. PubMed
Molecular response assessment by quantitative real-time polymerase chain reaction after induction therapy in NPM1-mutated patients identifies those at high risk of relapse.
Hubmann M, Köhnke T, Hoster E, Schneider S, Dufour A, Zellmeier E, Fiegl M, Braess J, Bohlander SK, Subklewe M, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Hiddemann W, Spiekermann K.
Haematologica. 2014 Aug;99(8):1317-25. doi: 10.3324/haematol.2014.104133. PubMed
Combination of Complement-Dependent Cytotoxicity and Relative Fluorescent Quantification of HLA Length Polymorphisms Facilitates the Detection of a Loss of Heterozygosity.
Witter K, Reibke R, Subklewe M, Zahn R, Kauke T, Spiekermann K, Spannagl M, Tischer J, Hiddemann W, Dick A.
Bone Marrow Res. 2014;2014:541345. doi: 10.1155/2014/541345. PubMed
Discovery of highly potent p53-MDM2 antagonists and structural basis for anti-acute myeloid leukemia activities.
Huang Y, Wolf S, Beck B, Köhler LM, Khoury K, Popowicz GM, Goda SK, Subklewe M, Twarda A, Holak TA, Dömling A.
ACS Chem Biol. 2014 Mar 21;9(3):802-11. doi: 10.1021/cb400728e. PubMed
Activating FLT3 mutants show distinct gain-of-function phenotypes in vitro and a characteristic signaling pathway profile associated with prognosis in acute myeloid leukemia.
Janke H, Pastore F, Schumacher D, Herold T, Hopfner KP, Schneider S, Berdel WE, Büchner T, Woermann BJ, Subklewe M, Bohlander SK, Hiddemann W, Spiekermann K, Polzer H.
PLoS One. 2014 Mar 7;9(3):e89560. doi: 10.1371/journal.pone.0089560. PubMed
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
Krupka C, Kufer P, Kischel R, Zugmaier G, Bögeholz J, Köhnke T, Lichtenegger FS, Schneider S, Metzeler KH, Fiegl M, Spiekermann K, Baeuerle PA, Hiddemann W, Riethmüller G, Subklewe M.
Blood. 2014 Jan 16;123(3):356-65. doi: 10.1182/blood-2013-08-523548. PubMed
2013
Structures of the human and Drosophila 80S ribosome.
Anger AM, Armache JP, Berninghausen O, Habeck M, Subklewe M, Wilson DN, Beckmann R.
Nature. 2013 May 2;497(7447):80-5. doi: 10.1038/nature12104. PubMed
Current strategies in immunotherapy for acute myeloid leukemia.
Lichtenegger FS, Schnorfeil FM, Hiddemann W, Subklewe M.
Immunotherapy. 2013 Jan;5(1):63-78. doi: 10.2217/imt.12.145. Review. PubMed
2012
CD86 and IL-12p70 are key players for T helper 1 polarization and natural killer cell activation by Toll-like receptor-induced dendritic cells.
Lichtenegger FS, Mueller K, Otte B, Beck B, Hiddemann W, Schendel DJ, Subklewe M.
PLoS One. 2012;7(9):e44266. doi: 10.1371/journal.pone.0044266. PubMed
Monoallelic CEBPA mutations in normal karyotype acute myeloid leukemia: independent favorable prognostic factor within NPM1 mutated patients.
Dufour A, Schneider F, Hoster E, Benthaus T, Ksienzyk B, Schneider S, Kakadia PM, Sauerland MC, Berdel WE, Büchner T, Wörmann B, Braess J, Subklewe M, Hiddemann W, Bohlander SK, Spiekermann K; AML CG study group..
Ann Hematol. 2012 Jul;91(7):1051-63. doi: 10.1007/s00277-012-1423-4. PubMed
Advanced systemic mastocytosis as a mimicker of metastatic clear cell renal cell carcinoma.
Walz C, Subklewe M, Horny HP, Flaig M, Reiter A, Kirchner T, Sotlar K.
Leuk Res. 2012 Jun;36(6):799-801. doi: 10.1016/j.leukres.2012.02.031. PubMed
2011
Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission.
Beck B, Dörfel D, Lichtenegger FS, Geiger C, Lindner L, Merk M, Schendel DJ, Subklewe M.
J Transl Med. 2011 Sep 13;9:151. doi: 10.1186/1479-5876-9-151. PubMed
2010
[Hematology 2010].
Dreyling M, Subklewe M, Braess J, Spiekermann K.
Dtsch Med Wochenschr. 2010 Jun;135(25-26):1322-5. doi: 10.1055/s-0030-1255163. Review. PubMed
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Weidmann E, Hess G, Chow KU, Krause SW, Subklewe M, Kruse J, Weisel KC, Soekler M, Kim SZ, Napieralski S, Rech J, Dreyling M, Jäger E, Mitrou PS.
Leuk Lymphoma. 2010 Mar;51(3):447-55. doi: 10.3109/10428190903580402. PubMed
2009
Hepatosplenic T-cell lymphoma in a patient with Crohn's disease.
Beigel F, Jürgens M, Tillack C, Subklewe M, Mayr D, Göke B, Brand S, Ochsenkühn T.
Nat Rev Gastroenterol Hepatol. 2009 Jul;6(7):433-6. doi: 10.1038/nrgastro.2009.87. Review. PubMed
2008
Epstein-Barr virus-associated B-cell lymphoma secondary to FCD-C therapy in patients with peripheral T-cell lymphoma.
Weisel KC, Weidmann E, Anagnostopoulos I, Kanz L, Pezzutto A, Subklewe M.
Int J Hematol. 2008 Nov;88(4):434-40. doi: 10.1007/s12185-008-0176-2. PubMed
2007
Generation of EBV-specific T cells for adoptive immunotherapy: a novel protocol using formalin-fixed stimulator cells to increase biosafety.
Hammer MH, Brestrich G, Mittenzweig A, Roemhild A, Zwinger S, Subklewe M, Beier C, Kurtz A, Babel N, Volk HD, Reinke P.
J Immunother. 2007 Nov-Dec;30(8):817-24. PubMed
Radiologic and pathologic features of a posttransplantation primary central nervous system lymphoma demonstrating Epstein-Barr virus-positive Hodgkin lymphoma.
Subklewe M, Anagnostopoulos I.
Clin Lymphoma Myeloma. 2007 Sep;7(8):535-7. PubMed
Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib.
Subklewe M, Sebelin-Wulf K, Beier C, Lietz A, Mathas S, Dörken B, Pezzutto A.
Hum Immunol. 2007 Mar;68(3):147-55. PubMed
2006
Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD.
Sebelin-Wulf K, Nguyen TD, Oertel S, Papp-Vary M, Trappe RU, Schulzki A, Pezzutto A, Riess H, Subklewe M.
Transpl Immunol. 2007 Apr;17(3):203-10. PubMed
Association of human leukocyte antigen haplotypes with posttransplant lymphoproliferative disease after solid organ transplantation.
Subklewe M, Marquis R, Choquet S, Leblond V, Garnier JL, Hetzer R, Swinnen LJ, Oertel S, Papp-Vary M, Gonzalez-Barca E, Hepkema BG, Schoenemann C, May J, Pezzutto A, Riess H.
Transplantation. 2006 Oct 27;82(8):1093-100. PubMed
Impairment of circulating myeloid dendritic cells in immunosuppressed renal/pancreas transplant recipients.
Sebelin K, Schulzki A, Kloetzel PM, Dörken B, Pezzutto A, Subklewe M.
Transplantation. 2006 Sep 27;82(6):779-87. PubMed
Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B.
Ann Hematol. 2006 Jul;85(7):478-84. PubMed
2005 and before
Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells.
Subklewe M, Sebelin K, Block A, Meier A, Roukens A, Paludan C, Fonteneau JF, Steinman RM, Münz C.
Hum Immunol. 2005 Sep;66(9):938-49. PubMed
Extramedullary manifestation of a donor-derived acute myeloid leukemia in a liver transplant patient.
Subklewe M, Nagy M, Schoch C, Jenisch S, Siebert R, Gesk S, Neuhaus P, Dörken B, Schmidt CA.
Leukemia. 2004 Dec;18(12):2050-3. PubMed
Dendritic cells for the induction of EBV immunity.
Subklewe M.
Recent Results Cancer Res. 2002;159:38-43. Review. PubMed
Dendritic cells cross-present latency gene products from Epstein-Barr virus-transformed B cells and expand tumor-reactive CD8(+) killer T cells.
Subklewe M, Paludan C, Tsang ML, Mahnke K, Steinman RM, Münz C.
J Exp Med. 2001 Feb 5;193(3):405-11. PubMed
Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.
Münz C, Bickham KL, Subklewe M, Tsang ML, Chahroudi A, Kurilla MG, Zhang D, O'Donnell M, Steinman RM.
J Exp Med. 2000 May 15;191(10):1649-60. PubMed
Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion.
Engelmayer J, Larsson M, Subklewe M, Chahroudi A, Cox WI, Steinman RM, Bhardwaj N.
J Immunol. 1999 Dec 15;163(12):6762-8. PubMed
Presentation of epstein-barr virus latency antigens to CD8(+), interferon-gamma-secreting, T lymphocytes.
Subklewe M, Chahroudi A, Bickham K, Larsson M, Kurilla MG, Bhardwaj N, Steinman RM.
Eur J Immunol. 1999 Dec;29(12):3995-4001. PubMed
Induction of Epstein-Barr virus-specific cytotoxic T-lymphocyte responses using dendritic cells pulsed with EBNA-3A peptides or UV-inactivated, recombinant EBNA-3A vaccinia virus.
Subklewe M, Chahroudi A, Schmaljohn A, Kurilla MG, Bhardwaj N, Steinman RM.
Blood. 1999 Aug 15;94(4):1372-81. PubMed
Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells.
Inaba K, Turley S, Yamaide F, Iyoda T, Mahnke K, Inaba M, Pack M, Subklewe M, Sauter B, Sheff D, Albert M, Bhardwaj N, Mellman I, Steinman RM.
J Exp Med. 1998 Dec 7;188(11):2163-73. PubMed
A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells.
Reddy A, Sapp M, Feldman M, Subklewe M, Bhardwaj N.
Blood. 1997 Nov 1;90(9):3640-6. PubMed
Expression of surface markers on alveolar macrophages from symptomatic patients with HIV infection as detected by flow cytometry.
Wasserman K, Subklewe M, Pothoff G, Banik N, Schell-Frederick E.
Chest. 1994 May;105(5):1324-34. PubMed